1244 related articles for article (PubMed ID: 27650638)
21. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
23. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
[TBL] [Abstract][Full Text] [Related]
24. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials.
Sawaya FJ; Morice MC; Spaziano M; Mehran R; Didier R; Roy A; Valgimigli M; Kim HS; Woo Park K; Hong MK; Kim BK; Jang Y; Feres F; Abizaid A; Costa RA; Colombo A; Chieffo A; Giustino G; Stone GW; Bhatt DL; Palmerini T; Gilard M
Catheter Cardiovasc Interv; 2017 Feb; 89(2):178-189. PubMed ID: 27426936
[TBL] [Abstract][Full Text] [Related]
25. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Harada Y; Michel J; Lohaus R; Mayer K; Emmer R; Lahmann AL; Colleran R; Giacoppo D; Wolk A; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tölg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Wöhrle J; Kufner S; Morath T; Ibrahim T; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Mehilli J; Byrne RA; Kastrati A; Schulz-Schüpke S
Thromb Haemost; 2017 Oct; 117(10):1989-1999. PubMed ID: 28783201
[TBL] [Abstract][Full Text] [Related]
26. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
[TBL] [Abstract][Full Text] [Related]
27. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
28. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
[TBL] [Abstract][Full Text] [Related]
29. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
30. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
31. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
32. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
[TBL] [Abstract][Full Text] [Related]
33. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
34. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.
Joyce LC; Baber U; Claessen BE; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Ariti C; Dangas G; Faggioni M; Aoi S; Gibson CM; Aquino M; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Guedeney P; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
JACC Cardiovasc Interv; 2019 May; 12(10):983-992. PubMed ID: 31122354
[TBL] [Abstract][Full Text] [Related]
35. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
36. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.
Baber U; Dangas G; Chandrasekhar J; Sartori S; Steg PG; Cohen DJ; Giustino G; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Weisz G; Colombo A; Pocock S; Mehran R
JACC Cardiovasc Interv; 2016 Jul; 9(13):1349-57. PubMed ID: 27388822
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Jiang M; You JHS
Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
[TBL] [Abstract][Full Text] [Related]
38. The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.
Li Q; Ren X; Yu X; He J; Gao Y; Zhang X; Wu C; Luo Y; Zhang Y; Chen F
Cardiovasc Ther; 2016 Jun; 34(3):127-37. PubMed ID: 26826703
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW
JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190
[TBL] [Abstract][Full Text] [Related]
40. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry.
Rossini R; Angiolillo DJ; Musumeci G; Capodanno D; Lettino M; Trabattoni D; Pilleri A; Calabria P; Colombo P; Bernabò P; Ferlini M; Ferri M; Tarantini G; De Servi S; Savonitto S
Catheter Cardiovasc Interv; 2017 Jan; 89(1):E13-E25. PubMed ID: 27404797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
